Misan Abu-Rmaileh excels as Chief Corporate Development Officer at NewBridge Pharmaceuticals in Dubai, masterminding strategic in-licensing and market entry for innovative FDA/EMA-approved therapies throughout the Middle East and North Africa. She spearheads product identification, in-depth market studies with sales forecasts, pricing strategies, and P&L evaluations, while coordinating cross-functionally with commercial, sales, and regulatory teams to address critical gaps in oncology, immunology, neuroscience, GI, and rare diseases.
Through her leadership, NewBridge has secured transformative partnerships with industry giants including Eisai, UCB, Sunovion, EUSA, Intercept, Camurus, and BeiGene, cementing its role as MENA’s foremost specialty pharmaceutical innovator.
Misan’s trajectory at NewBridge encompasses Executive VP Corporate & Business Development, VP Business Development, Business Development Director MENA, Head of Business Development MENA, Senior BD Manager AfMET, and BD Manager AfMET. Her prowess in strategic negotiations, distributor vetting, deal closure, and shaping the company’s 5-Year Business Plan drives sustained growth.
Building on roles as Commercial Business Development Services Manager at Aspen Healthcare and Senior Licensing Associate at Hikma Pharmaceuticals, she mastered project management and international expansion. A University of Jordan pharmacy graduate and UWC Mahindra College IB alumnus, Misan dominates in data-driven insights, partnership development, and executive strategy.
Featured alongside CEO Joe Henein at J.P. Morgan Healthcare and BIO conferences, Misan propels NewBridge into underserved MENA territories.
Misan Abu-Rmaileh’s deal-making acumen and forward-thinking vision accelerate pharmaceutical access, delivering life-changing therapies with unparalleled precision.